Sandra Meta Swain MD

Professor, Medicine, Georgetown University School of Medicine

8901 Wisconsin Ave Bldg 8 Room 5101Bethesda, MD 20889
Phone+1 301-435-5416
Fax+1 301-496-0047

Dr. Swain is on Doximity

As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Swain's full profile Already have an account?

Education & Training

National Institutes of Health Clinical CenterFellowship, Hematology and Medical Oncology, 1983 - 1986
Vanderbilt University Medical CenterResidency, Internal Medicine, 1980 - 1983
University of Florida College of MedicineClass of 1980

The following disclaimer is related to board certifications obtained from ABMS®, denoted by the ABMS® logo.

This information is proprietary data maintained in a copyrighted database owned by the American Board of Medical Specialties®. The display and presence of ABMS Data in no way constitutes any affiliation, association with, or endorsement of any advertising, promotion, or sponsorship by ABMS and its affiliates and subsidiaries, the ABMS Member Boards, or ABMS board certified physicians and medical specialists. Copyright 2026 American Board of Medical Specialties®. All rights reserved.

The user is responsible for ensuring that the profile obtained in this directory is the profile of the physician or medical specialist being sought.

A self-designated specialty, subspecialty, or practice area neither implies nor is equivalent to ABMS board certification or the existence of specialized training by or competence of a physician or medical specialist.

Certifications & Licensure

MD State Medical License 1983 - 2027
DC State Medical License 1988 - 2026
TX State Medical License 1996 - 2024
IL State Medical License 1989 - 2014
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification ARIA oncology information system (for Medical Oncology), Varian Medical Systems, 2013, 2015-2016
CMS Meaningful Use Stage 2 Certification ARIA Oncology Information System (for Medical Oncology), Varian Medical Systems, 2013, 2015-2016
CMS Meaningful Use Stage 2 Certification MEDSEEK Empower, SymphonyCare, LLC, 2013, 2015-2016

Clinical Trials

Ixabepilone in Treating Patients With Locally Advanced or Metastatic Breast Cancer
COMPLETED
PHASE2
Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Positive Breast Cancer
COMPLETED
PHASE3
Solid Tumors Using Ixabepilone and Dasatinib
COMPLETED
PHASE1

Publications & Presentations

PubMed

Sex-based prognosis in industry-sponsored advanced solid tumor trials: an individual participant data meta-analysis of survival and adverse events.
Rakchha Chhetri, Natansh D Modi, Bradley D Menz, Erik Cornelisse, David Postma
Journal of the National Cancer Institute. 2026-07-01
AI-powered and manual assessment of tumor-infiltrating lymphocytes in early HER2-positive breast cancer in NSABP B-41.
Ilana Schlam, Gong Tang, Khalid AbdulJabbar, Haixi Yan, Xuelin Gu
NPJ Breast Cancer. 2026-05-14
2 citations
Characterization of the safety profile of trastuzumab deruxtecan by dose: a pooled analysis across DESTINY studies.
Yeon Hee Park, Javier Cortes, Shanu Modi, Sara A Hurvitz, Giampaolo Bianchini
The Oncologist. 2025-12-27

Journal Articles

Left Ventricular Ejection Fraction Monitoring Adherence Rates
Chau T Dang, Sandra M Swain, Anne Blaes, ScienceDirect
Take Care of Your Neighborhood
Elmer E Huerta, Sandra M Swain, Breast Cancer Research and Treatment

Lectures

NSABP B-41, a randomized neoadjuvant trial: Genes and signatures associated with pathologic complete response (pCR).
2019 ASCO Annual Meeting - 6/1/2019
End-of-study analysis from the phase III, randomized, double-blind, placebo (Pla)-controlled CLEOPATRA study of first-line (1L) pertuzumab (P), trastuzumab (H), and do...
2019 ASCO Annual Meeting - 6/1/2019
Intrinsic subtypes of HER2-positive breast cancer and their associations with pathologic complete response (pCR) and outcomes: Findings from NSABP B-41, a randomized n...
2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018

Press Mentions

Celebrating a Milestone in Cancer ResearchAugust 8th, 2025
Charles B. Hammond, M.D.,September 30th, 2024
NanoString Announces the Creation of the GeoMx Breast Cancer ConsortiumDecember 11th, 2019